Research map: Therapeutic management of axial spondyloarthritis: summary of 2024 update of the Spanish clinical practice guideline (ESPOGUIA)

Back to the article

Papers in this map

  1. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations · Gordon Henry Guyatt · 2008 · 23433 citations · Cited by this paper
  2. A transfer learning–based approach for automated bone fracture classification in X-ray imaging · 2026 · Related
  3. AGREE II: advancing guideline development, reporting and evaluation in health care · Melissa C. Brouwers · 2010 · 3831 citations · Cited by this paper
  4. The causal relationship between cathepsins and ankylosing spondylitis: a two-sample Mendelian randomization study · 2026 · Related
  5. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update · Sofía Ramiro · 2022 · 996 citations · Cited by this paper
  6. High-dose folic acid supplement is associated with increased cardiovascular risk in rheumatoid arthritis patients on methotrexate · 2026 · Related
  7. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise · Holger Jens Schünemann · 2013 · 719 citations · Cited by this paper
  8. Temporal trends and future projections of hand osteoarthritis burden in China from 1990 to 2021 · 2026 · Related
  9. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial · Dominique Baeten · 2013 · 601 citations · Cited by this paper
  10. Towards an individualised approach to pain management in inflammatory arthritis · 2026 · Related
  11. The Impact of Tumor Necrosis Factor α Inhibitors on Radiographic Progression in Ankylosing Spondylitis · Nigil Haroon · 2013 · 493 citations · Cited by this paper
  12. Patient and public involvement in musculoskeletal pain research: using mutual learning to improve research quality · 2026 · Related
  13. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years · Désirée M F M van der Heijde · 2009 · 414 citations · Cited by this paper
  14. Cardiometabolic disease and risk of total knee arthroplasty among patients with knee osteoarthritis receiving intra-articular hyaluronic acid: a real-world cohort study · 2026 · Related
  15. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study · Désirée M F M van der Heijde · 2017 · 378 citations · Cited by this paper
  16. Early identification of difficult-to-manage axial spondyloarthritis using machine-learning decision trees · 2026 · Related
  17. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial · Désirée M F M van der Heijde · 2018 · 374 citations · Cited by this paper
  18. Persistence of IL-17 and TNF inhibitors following initial TNF inhibitor use in axial spondyloarthritis: a nationwide retrospective cohort study · 2026 · Related
  19. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial · Désirée M F M van der Heijde · 2019 · 359 citations · Cited by this paper
  20. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis · Xenofon Baraliakos · 2013 · 322 citations · Cited by this paper
  21. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study · Jürgen Braun · 2016 · 275 citations · Cited by this paper
  22. Impact of patient involvement on clinical practice guideline development: a parallel group study · Melissa J. Armstrong · 2018 · 217 citations · Cited by this paper
  23. EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis · Yvonne van Eijk‐Hustings · 2011 · 180 citations · Cited by this paper
  24. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update · Linda Rüegg · 2025 · 164 citations · Cited by this paper
  25. Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study · Clementina López‐Medina · 2021 · 146 citations · Cited by this paper
  26. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial · Atul A. Deodhar · 2022 · 142 citations · Cited by this paper
  27. Axial spondyloarthritis · Victoria Navarro‐Compán · 2025 · 130 citations · Cited by this paper
  28. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study · Robert Landewé · 2018 · 101 citations · Cited by this paper
  29. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis · Atul A. Deodhar · 2017 · 86 citations · Cited by this paper
  30. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction · Robert Landewé · 2020 · 73 citations · Cited by this paper
  31. Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review · Chrysoula G. Gialouri · 2023 · 61 citations · Cited by this paper
  32. Long‐term effects of a nurse‐led group and individual patient education programme for patients with chronic inflammatory polyarthritis – a randomised controlled trial · Kjersti Grønning · 2013 · 60 citations · Cited by this paper
  33. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies · Xenofon Baraliakos · 2023 · 56 citations · Cited by this paper
  34. Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control Trial · Max M. Yates · 2015 · 53 citations · Cited by this paper
  35. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis · The REDES-TNF investigators · 2019 · 53 citations · Cited by this paper
  36. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort · Raphael Micheroli · 2020 · 52 citations · Cited by this paper
  37. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y) · Robert Landewé · 2021 · 39 citations · Cited by this paper
  38. Impact of different types of exercise programs on ankylosing spondylitis: a systematic review and meta-analysis · Rayane Boudjani · 2022 · 39 citations · Cited by this paper
  39. Do Obesity and Overweight Influence Disease Activity Measures in Axial Spondyloarthritis? A Systematic Review and Meta‐Analysis · Augusta Ortolan · 2020 · 38 citations · Cited by this paper

Source: OpenAlex (CC0)